INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molecular and immunological tests for tuberculosis (TB) in the European setting. METHODS: Web-based survey of Paediatric-Tuberculosis-Network-European-Trialsgroup (ptbnet) and Tuberculosis-Network-European-Trialsgroup (TBnet) members conducted June to December 2013. Both networks comprise clinicians, microbiologists, epidemiologists and researchers predominately based in Europe. RESULTS: 191 healthcare professionals from 31 European countries participated. Overall, 26.8% of respondents did not have access to the Xpert MTB/RIF assay; only 44.6% had access to the assay in-house. However, a substantial proportion had access to other commercial and/or...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
Laboratory confirmation of paediatric tuberculosis (TB) is frequently lacking. We reviewed the range...
Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines...
INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molec...
INTRODUCTION Currently only limited data exist regarding the availability and clinical use of mol...
<div><p>Introduction</p><p>Currently only limited data exist regarding the availability and clinical...
INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molec...
Objective: To determine the current use and potential acceptance (by tuberculosis experts worldwide)...
Laboratory confirmation of paediatric tuberculosis (TB) is frequently lacking. We reviewed the range...
CITATION: Amicosante, M., et al. 2017. Current use and acceptability of novel diagnostic tests for a...
The lack of capacity to provide laboratory confirmation of a diagnosis of tuberculosis disease (TB) ...
INTRODUCTION: Tuberculous meningitis (TBM) is often diagnostically challenging. Only limited data ex...
Altres ajuts: The authors would like to acknowledge Hain Lifescience (Germany) for their provision o...
The World Health Organization (WHO) recently revised its guidelines for rapid diagnosis of drug-resi...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
Laboratory confirmation of paediatric tuberculosis (TB) is frequently lacking. We reviewed the range...
Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines...
INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molec...
INTRODUCTION Currently only limited data exist regarding the availability and clinical use of mol...
<div><p>Introduction</p><p>Currently only limited data exist regarding the availability and clinical...
INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molec...
Objective: To determine the current use and potential acceptance (by tuberculosis experts worldwide)...
Laboratory confirmation of paediatric tuberculosis (TB) is frequently lacking. We reviewed the range...
CITATION: Amicosante, M., et al. 2017. Current use and acceptability of novel diagnostic tests for a...
The lack of capacity to provide laboratory confirmation of a diagnosis of tuberculosis disease (TB) ...
INTRODUCTION: Tuberculous meningitis (TBM) is often diagnostically challenging. Only limited data ex...
Altres ajuts: The authors would like to acknowledge Hain Lifescience (Germany) for their provision o...
The World Health Organization (WHO) recently revised its guidelines for rapid diagnosis of drug-resi...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
Laboratory confirmation of paediatric tuberculosis (TB) is frequently lacking. We reviewed the range...
Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines...